Results 101 to 110 of about 44,917 (208)

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

open access: yesMolecular Oncology, Volume 20, Issue 7, Page 1694-1712, July 2026.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski   +12 more
wiley   +1 more source

Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo

open access: yesAdvanced Science, Volume 13, Issue 38, 9 July 2026.
Dual priming with minocycline and photodynamic priming reprograms the pancreatic tumor microenvironment to overcome chemoresistance. By suppressing DNA repair enzyme Tdp1, inducing photooxidative damage, and enhancing irinotecan delivery via light‐activated nanoencapsulation, this strategy remodels the tumor microenvironment and drives immune ...
Fernanda V. Cabral   +7 more
wiley   +1 more source

Primary Tumor Resection in Patients With Unresectable Metastatic Colorectal Cancer: A Systematic Review and Meta‐Analysis

open access: yesAnnals of Gastroenterological Surgery, Volume 10, Issue 4, Page 1008-1020, July 2026.
This systematic review and meta‐analysis evaluated the role of primary tumor resection (PTR) in asymptomatic patients with unresectable metastatic colorectal cancer. Across 17 eligible studies including 9317 patients, PTR did not improve overall or progression‐free survival compared with chemotherapy alone.
Junpei Takashima   +3 more
wiley   +1 more source

Comparison Between Upfront Surgery and Preoperative Chemotherapy for CY1P0 Gastric Cancer: A Japanese Sub‐Analysis of CONVO‐GC‐1

open access: yesAnnals of Gastroenterological Surgery, Volume 10, Issue 4, Page 1021-1030, July 2026.
ABSTRACT Background Radical gastrectomy, followed by adjuvant chemotherapy has been a common practice in Japan for peritoneal lavage cytology‐positive (CY1) but peritoneal dissemination‐negative (P0) stage IV gastric cancer. This study aimed to clarify the differences in treatment outcomes between upfront surgery and preoperative chemotherapy, followed
Kenichiro Furukawa   +12 more
wiley   +1 more source

Preoperative Gemcitabine/Nab‐Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone

open access: yesAnnals of Gastroenterological Surgery, Volume 10, Issue 4, Page 1209-1216, July 2026.
ABSTRACT Background Although NCCN guidelines recommend preoperative therapy for borderline resectable pancreatic cancer (BR‐PC), it is still unclear which regimen is better. The study objective was to elucidate the prognostic significance of neoadjuvant chemoradiotherapy (NACRT) with gemcitabine/nab‐paclitaxel (GnP‐RT) compared to gemcitabine alone ...
Hirofumi Akita   +9 more
wiley   +1 more source

Relationship Between the Product of Pre‐Treatment Neutrophil and Monocyte Counts and Clinical Outcomes in Rectal Cancer With Suspected Lateral Lymph Node Metastasis

open access: yesAnnals of Gastroenterological Surgery, Volume 10, Issue 4, Page 1097-1106, July 2026.
ABSTRACT Aim A novel systemic inflammatory response marker, the neutrophil × monocyte value (NM value), has been identified as a negative predictive factor for responses to chemoradiotherapy in rectal cancer. However, the clinical implications of the NM value remain unknown.
Takayoshi Sasaki   +9 more
wiley   +1 more source

Mesoporous Silica Nanoparticles With Customized Drug Ratio/Loading for Effective Treatment of Gemcitabine‐Resistant Pancreatic Tumors

open access: yesAdvanced NanoBiomed Research, Volume 6, Issue 7, July 2026.
Redox responsive mesoporous silica nanoparticles (MSNs) were engineered to deliver gemcitabine (Gem) and cisplatin (cisPt) at defined ratios to overcome chemoresistance in pancreatic ductal adenocarcinoma (PDAC). Optimized Gem MSNs and Gem cisPt MSNs enhanced cytotoxicity in murine and human Gem resistant models, with select formulations inducing ...
Tamanna Binte Huq   +5 more
wiley   +1 more source

Watch and Wait Strategy for Locally Advanced Rectal Cancer: Update From Results of Recent Clinical Trials

open access: yesCancer Medicine, Volume 15, Issue 7, July 2026.
ABSTRACT Locally advanced rectal cancer (LARC) is a common malignant tumor in the digestive system. Currently, despite growing recognition of personalized medicine, systematic risk stratification and full incorporation of patient preferences for anal preservation and treatment tolerance remain challenging in some clinical settings.
Ruocheng Yin   +4 more
wiley   +1 more source

Irinotecan Modulates Immune Checkpoints in Neuroblastoma. [PDF]

open access: yesImmunotargets Ther
Lapidus T   +4 more
europepmc   +1 more source

Oxaliplatin‐induced neuropathy after total neoadjuvant therapy for rectal cancer: Dose–response relationship and impact on quality of life

open access: yesInternational Journal of Cancer, Volume 159, Issue 1, Page 198-209, 1 July 2026.
What's New? Oxaliplatin serves a key role in the treatment of rectal cancer, though it is a significant cause of chemotherapy‐induced peripheral neuropathy. As total neoadjuvant therapy, in which all therapy is given before surgery, has become more common, understanding neuropathy has grown increasingly important. This study examined neuropathy and its
Georg W. Wurschi   +29 more
wiley   +1 more source

Home - About - Disclaimer - Privacy